Post-liver transplantation de novo hepatitis with overlap features

2005 ◽  
Vol 55 (10) ◽  
pp. 660-664 ◽  
Author(s):  
Andrew P. Keaveny ◽  
Fredric D. Gordon ◽  
Urmila Khettry
Keyword(s):  
Liver Transplantation ◽  
De Novo

scholarly journals De novo gastric cancer developing after liver transplantation from deceased donor for biliary atresia: a case report

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Naruki Higashidate ◽  
Suguru Fukahori ◽  
Shinji Ishii ◽  
Nobuyuki Saikusa ◽  
Naoki Hashizume ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Liver Transplantation ◽  
Biliary Atresia ◽  
De Novo ◽  
Epigastric Pain ◽  
Gastroesophageal Junction ◽  
Deceased Donor ◽  
Lymphoproliferative Disease ◽  
Endoscopic Examination ◽  
De Novo Malignancy

Abstract Background Apart from Kasai’s procedure, liver transplantation (LTx) has dramatically improved the outcome of children with biliary atresia (BA). However, de novo malignancy has been reported to be one of the major causes of late mortality after LTx among adults. We report a rare case of de novo gastric cancer developing after LTx for BA received during childhood. Case presentation A 21-year-old male patient who had undergone LTx for BA at age 2 years occasionally visited our outpatient clinic due to symptoms of epigastric pain and dysphagia. Endoscopic examination and computed tomography revealed advanced gastric cancer at the gastroesophageal junction with multiple liver metastases. Despite systemic chemotherapy, the disease progressed, resulting in patient’s death 2 years after the diagnosis. Conclusions De novo malignancy in the absence of post-transplant lymphoproliferative disease is rare in pediatric patients who received LTx. To the best of our knowledge, no report has been available on the development of gastric cancer after LTx for BA during childhood. Primary physicians should therefore establish a follow-up plan for patients receiving LTx for BA considering the potential for the development of de novo malignancy, including gastric cancer, despite its rarity.

De Novo Tumors Are a Major Cause of Late Mortality After Orthotopic Liver Transplantation

2009 ◽  
Vol 41 (4) ◽  
pp. 1303-1305 ◽  
Author(s):  
U. Baccarani ◽  
G.L. Adani ◽  
D. Serraino ◽  
D. Lorenzin ◽  
M. Gambato ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Orthotopic Liver Transplantation ◽  
De Novo ◽  
Late Mortality ◽  
De Novo Tumors

De Novo Tumours after Liver Transplantation: Does Prevalence Increase with Aging? A Single Center Experience

2012 ◽  
Vol 94 (10S) ◽  
pp. 602
Author(s):  
M. G. Fernandez ◽  
D. Loredo ◽  
F. Gruz ◽  
S. Raffa ◽  
S. Yantorno ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
De Novo ◽  
Single Center ◽  
Single Center Experience

scholarly journals De novo and recurrence of metabolic dysfunction-associated fatty liver disease after liver transplantation

2021 ◽  
Vol 13 (12) ◽  
pp. 1991-2004
Author(s):  
Ma Ai Thanda Han ◽  
Raquel Olivo ◽  
Catherine J Choi ◽  
Nikolaos Pyrsopoulos
Keyword(s):  
Liver Transplantation ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
De Novo ◽  
Metabolic Dysfunction

scholarly journals Safety and Immunogenicity of Standard and Double Doses of Hepatitis B Vaccine in Children after Liver Transplantation: An Open-Label, Randomised Controlled Trial

Vaccines ◽  
2022 ◽  
Vol 10 (1) ◽  
pp. 92
Author(s):  
Palittiya Sintusek ◽  
Supranee Buranapraditkun ◽  
Piyaporn Wanawongsawad ◽  
Nawarat Posuwan ◽  
Pattarawat Thantiworasit ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Hepatitis B ◽  
De Novo ◽  
Controlled Trial ◽  
Geometric Mean ◽  
Interferon Γ ◽  
Specific Response ◽  
Open Label ◽  
High Prevalence ◽  
Randomised Controlled

A high prevalence of hepatitis B (HepB) antibody loss after liver transplantation (LT) and de novo HepB infection (DNH) was documented, hence revaccination to prevent DNH is crucial. This study aimed to compare the safety and immunogenicity of two HepB vaccine regimens in liver-transplanted children. Liver-transplanted children who were previously immunised but showed HepB surface antibodies (anti-HBs) ≤ 100 mIU/mL were randomised to receive a standard three-dose (SD) and double three-dose (DD) vaccine intramuscularly in months 0–1–6. Anti-HBs and T-cell-specific response to the HepB antigen were assessed. A total of 61 children (54.1% male, aged 1.32 ± 1.02 years) completed the study without any serious adverse reaction. The seroprotective rate was 69.6% vs. 60% (p = 0.368) and 91.3% vs. 85% (p = 0.431) in SD and DD after the first and third 3-dose vaccinations, respectively. The geometric mean titre (95% confidence interval) of anti-HBs in SD and DD were 443.33 (200.75–979.07) vs. 446.17 (155.58–1279.50) mIU/mL, respectively, at completion. Numbers of interferon-γ-secreting cells were higher in hyporesponders/responders than in nonresponders (p = 0.003). The significant factors for the immunologic response to HepB vaccination were anti-HB levels prevaccination, tacrolimus trough levels, and time from LT to revaccination. SD and DD had comparative immunogenicity and were safe for liver-transplanted children who were previously immunised.

scholarly journals THERAPY OF RECURRENT HEPATITIS C AFTER TRANSPLANTATION OF THE LIVER WITH DIRECT ACTING ANTI-HEPATITIS C VIRUS DRUGS: EXPERIENCE OF THREE RUSSIAN CENTERS

2018 ◽  
Vol 23 (1) ◽  
pp. 4-14
Author(s):  
Vladimir E. Syutkin ◽  
E. N Bessonova ◽  
M. N Davydenko
Keyword(s):  
Liver Transplantation ◽  
Hepatitis C ◽  
De Novo ◽  
Virologic Response ◽  
Resistance Mutations ◽  
Virus Genotype ◽  
Serious Adverse Events ◽  
Recurrent Hepatitis ◽  
Recurrent Hepatitis C ◽  
Direct Acting

The results of a retrospective analysis of the experience of three Russian regional liver transplantation centers in relation to antiviral therapy of recurrent hepatitis C in liver recipients are presented. There were studied six different therapeutic schedules with direct antiviral drugs (DAVD) administered in 91 patients. The frequency of the persistent virologic response in 12 weeks after the completion of therapy (PVR12) amounted to 92.3%. In recipients, the use of a combination of sofosbuvir and daclatasvir seems to be the most promising as following its administration relapses observed in only 3 out of the 57 recipients were associated with drug resistance mutations to NS5A inhibitors. There were no serious adverse events related to the use of DAVD. The frequency of the reactivation of HBV infection against the background of DAVD therapy in liver recipients did not exceed the previously reported frequency of de novo hepatitis B in non-endemic regions. In recurrent hepatitis C patients after the liver transplantation effects of both the virus genotype, the pronouncement of graft fibrosis and the addition of ribavirin, on the frequency of SVO12 have not been revealed.

Sign in / Sign up

Export Citation Format

Share Document